Multiple sclerosis (MS) is an inflammatory disease affecting the central nervous system that causes damage to myelin, neurons and axons, and which results in neurodegeneration. Identification of useful blood biomarkers for MS is still a challenge.
Duality Biologics (Suzhou) Co. Ltd. has presented data describing the discovery and preclinical results of DB-1303, an antibody-drug conjugate containing a trastuzumab biosimilar targeting HER2 (BAT0606), an exatecan derivative payload with topoisomerase I inhibitory activity (P1003) and an enzymatic ally cleavable tetrapeptide-maleimide-linker (payload-linker named L101P1003).
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has described nonreceptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of psoriasis, asthma, type 1 diabetes, inflammatory bowel disease, gout, multiple sclerosis, rheumatoid arthritis and TNF receptor-associated periodic syndrome (TRAPS), among others.
Kallyope Inc. has synthesized glucose-dependent insulinotropic receptor (GDIR; GPR119) agonists reported to be useful for the treatment of metabolic and nutrition disorders.
Halia Therapeutics Inc. has disclosed serine/threonine-protein kinase Nek7 inhibitors reported to be useful for the treatment of cancer, asthma, obesity, type 2 diabetes, hepatitis, peritonitis, neurodegeneration and psoriasis, among others.
Sequencing of a total of 16 individuals from 4 multiplex families representing rare and diverse anorectal malformation (ARM) types, as well as 3 surgically resected tissue specimens, resulted in the identification of a novel paternally inherited heterozygous CDX2 variant [c.722A>G (p.Glu241Gly)].
Interleukin-2 (IL-2) plays essential roles in immune system function, controlling tolerance and immunity. From the thymus, IL-2 prevents autoimmune disease by promoting the differentiation of immature T cells to regulatory T cells (Tregs).
RSS
